All posts

Dialogue Health shareholders should take Sun Life deal, Paradigm says

The Sun Life offer to acquire Dialogue Health Technologies (Dialogue Health Technologies Stock Quote, Chart, New, Analysts TSX:CARE) is “very compelling” for the latter’s shareholders, says Paradigm Capital analyst Daniel Rosenberg.

On Wednesday, CARE announced it had entered into has a definitive arrangement that would see all its shares acquired by Sun Life Financial at a price of $5.15 per share.

“In recent years, Dialogue has developed a strong relationship with Sun Life, Dialogue CEO Cherif Habib said. “This transaction represents an attractive opportunity for the company’s stakeholders. As a stand-alone entity backed by Sun Life, Dialogue will have more resources to deliver on our mission of helping people improve their health and well-being and the flexibility to continue to deliver on our mission by leveraging the respective strengths of both organizations. We are enthusiastic about the prospects of this next chapter in Dialogue’s history.”

With Wednesday’s report, Rosenberg changed his rating on CARE from “Hold” to “Tender”. The analyst explained why he liked the deal, even though he does not see significant synergies between the acquirer and the acquiree.

“We initiated coverage on Dialogue on October 14, 2022 at a price of $2.64, so today’s announced deal represents an attractive return and speaks to the value that strategics are willing to pay,” he said. “We continue to believe in Dialogue’s long-term vision and expect it to emerge a market share leader in digital health and wellness within Canada. Given the very attractive proposal from Sun Life, we are moving to a Tender rating (was Hold) and our target price to $5.15 (was $4.30).”

“At $5.15, the deal represents a 43.1% premium to the previous close and well above the 52-week high of $4.16. We value the transaction at ~3.2x EV/2024 revenue, notable premium to our group of peers trading at 1.7x,” the analysts added. “Though still a far cry from the $12.00 IPO, we view the offer price a very attractive to Dialogue shareholders in the context of the current market environment.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: care
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

SSTI is a buy, Roth says

Its first quarter results are in the book and Roth MKM analyst Richard K Baldry is still bullish on SoundThinking… [Read More]

2 hours ago

GLXY wins price target raise at ATB Capital

Following the company's first quarter results, ATB Capital Markets analyst Martin Toner has raised his price target on Galaxy Digital… [Read More]

10 hours ago

Paradigm cuts price target on TTNM

Following first quarter results he describes as "mixed" Paradigm Capital analyst Alexandra Ricci has cut her price target on Titanium… [Read More]

12 hours ago

Buy ATS ahead of Q4 earnings, Stifel says

Ahead of the company's fourth quarter earnings report, due May 16, Stifel analyst Justin Keywood says ATS Corp (ATS Corp… [Read More]

1 day ago

Ormat Technologies is a buy, Roth says

Its first quarter results are in the books and Roth MKM analyst Justin Clare thinks there is money to be… [Read More]

1 day ago

Cannabist stock is a buy, Beacon says

Beacon analyst Russell Stanley says the most recent results were better than expected for The Cannabist Company (The Cannabist Company… [Read More]

1 day ago